Mizuho Maintains Outperform on Immix Biopharma, Lowers Price Target to $22

Benzinga · 3d ago
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and lowers the price target from $23 to $22.